Kiora Pharmaceuticals AI Stock Analysis
Want to see KPRX full AI Analyst Report?
Kiora Pharmaceuticals (KPRX) AI Stock Analysis
Kiora Pharmaceuticals
(NASDAQ:KPRX)
The score is held down primarily by weak financial performance (ongoing losses, unstable revenue, and negative free cash flow) and bearish technical momentum (price far below key moving averages with negative MACD). Positive pipeline/licensing and leadership events provide some support, but valuation is not a clear positive due to negative earnings and no dividend yield data.
Kiora Pharmaceuticals (KPRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 32.08K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.17
- Revenue Growth
- ―
- EPS Growth
- -18.90%
- Country
- US
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Kiora Pharmaceuticals Business Overview & Revenue Model
Company Description
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candid...
How the Company Makes Money
As a clinical-stage biotech, Kiora Pharmaceuticals does not have an established, recurring product-sales business in the way commercial-stage pharmaceutical companies do. Publicly available information about Kiora’s specific, ongoing revenue-generati...
Kiora Pharmaceuticals Financial Statement Overview
Summary
Overall fundamentals are weak due to persistent losses and cash burn: TTM revenue is ~$1.0M with a net loss of ~$12.8M and negative margins, and operating/free cash flow are negative (FCF about -$7.8M to -$7.9M). The balance sheet is a partial offset with very low leverage (debt-to-equity ~0.02), but returns are sharply negative (ROE about -82%) and results have been volatile (profitable 2024 followed by zero-revenue losses in 2025).
Income Statement
18Very NegativeBalance Sheet
68PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00M | 0 | 16.00M | 0 | 0 | 0 |
| Gross Profit | 903.94K | -24.80K | 16.00M | 0 | 0 | 0 |
| EBITDA | -11.27M | -12.07M | 5.70M | -12.36M | -13.65M | -13.91M |
| Net Income | -12.76M | -10.84M | 3.59M | -12.51M | -13.58M | -13.77M |
Balance Sheet | ||||||
| Total Assets | 22.37M | 24.25M | 36.48M | 13.71M | 18.68M | 20.13M |
| Cash, Cash Equivalents and Short-Term Investments | 16.29M | 17.09M | 26.79M | 2.45M | 5.96M | 7.85M |
| Total Debt | 286.79K | 368.26K | 57.17K | 106.89K | 105.78K | 209.41K |
| Total Liabilities | 7.08M | 8.13M | 10.72M | 7.60M | 7.27M | 5.55M |
| Stockholders Equity | 15.30M | 16.13M | 25.76M | 6.11M | 11.41M | 14.58M |
Cash Flow | ||||||
| Free Cash Flow | -7.90M | -10.07M | 8.55M | -9.56M | -10.43M | -10.74M |
| Operating Cash Flow | -7.79M | -9.96M | 8.56M | -9.56M | -10.43M | -10.68M |
| Investing Cash Flow | 2.90M | 14.43M | -22.66M | 0 | 6,375 | -157.02K |
| Financing Cash Flow | 4.91M | 265.65K | 15.50M | 5.97M | 8.62M | 17.58M |
Kiora Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Negative. The current price of 0.98 is below the 20-day moving average (MA) of 1.76, below the 50-day MA of 2.25, and below the 200-day MA of 2.37, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 16.98 is Positive, neither overbought nor oversold. The STOCH value of 2.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPRX.
Kiora Pharmaceuticals Risk Analysis
Kiora Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Kiora Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksKiora Pharmaceuticals Peers Comparison
Overall Rating
KPRX46Neutral
GTBP43Neutral
BCDA41Neutral
INAB41Neutral
KALA41Neutral
BRTX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $4.34M | -0.34 | -82.06% | ― | ― | -18.90% | |
| 43Neutral | $7.29M | -0.03 | -443.08% | ― | ― | 75.09% | |
| 41Neutral | $11.96M | -1.26 | -912.37% | ― | ― | 62.51% | |
| 41Neutral | $8.82M | -0.70 | -93.66% | ― | ― | 81.16% | |
| 41Neutral | $2.47M | -0.00 | -222.32% | ― | ― | 78.25% | |
| 38Underperform | $1.96M | -0.06 | -423.84% | ― | -8.47% | 25.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KPRX | Kiora Pharmaceuticals, Inc. | 0.98 | -0.94 | -48.85% | |
| GTBP | Gt Biopharma, Inc. | 3.54 | -13.46 | -79.21% | |
| KALA | Kala Bio, Inc. | 3.83 | -945.67 | -99.60% | |
| BRTX | Biorestorative Therapies, Inc. | 1.42 | -27.18 | -95.03% | |
| BCDA | Biocardia | 0.79 | -0.53 | -40.15% | |
| INAB | In8bio, Inc. | 0.82 | -0.80 | -49.63% |
Kiora Pharmaceuticals Corporate Events
Kiora Pharmaceuticals Licenses KIO-401, Refocuses Pipeline Strategy
PositiveOn October 23, 2026, Kiora Pharmaceuticals entered into an exclusive license agreement with Japan-based Senju Pharmaceutical to in-license KIO-401, an oral neuroprotective calpain inhibitor, securing development and commercialization rights outside A...
Kiora Pharmaceuticals Bolsters Leadership in Clinical Development
PositiveOn September 8, 2026, Kiora Pharmaceuticals appointed Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs, strengthening its leadership in ophthalmic drug development. Lane brings more than 20 years of experience...
Kiora Licenses KIO-301 Rights in South Korea
PositiveOn August 20, 2026, Kiora Pharmaceuticals entered an exclusive license and development agreement with Chong Kun Dang Pharmaceutical Corporation granting CKD rights to develop, manufacture and commercialize its KIO-301 molecular photoswitch in South K...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
